Sections
Shortcuts
News

Actavis to buy Forest Labs in $25 billion deal

This is a summary. To read the whole story subscribe to BostonGlobe.com

Actavis PLC plans to buy Forest Laboratories Inc. for about $25 billion, catapulting little-known Actavis into the world’s No. 15 drugmaker, with an unusual one-stop-shopping model giving it an edge: more face time with doctors.

U.S. physicians, increasingly crunched for time, keep reducing how many drugmaker sales reps they see. Forest gives Actavis not just a broader product line, but also its big U.S. sales force, which now can promote a half-dozen Forest and Actavis products at each doctor visit. That likely will result in more time and more options to present to primary care doctors, compared to rival brand-name drugmakers whose sales reps promote one or two drugs.

Full story for BostonGlobe.com subscribers.

Get the full story with unlimited access to BostonGlobe.com.

Just 99 cents for four weeks.

Sections
Shortcuts

Share